Agents and Actions

, Volume 21, Issue 3–4, pp 306–309 | Cite as

Effect of selected antiinflammatory agents and other drugs on zymosan, arachidonic acid, PAF and carrageenan induced paw edema in the mouse

  • W. Calhoun
  • J. Chang
  • R. P. Carlson
Models of Inflammation and Arthritis


Zymosan, carrageenan, arachidonic acid and platelet activating factor (PAF) were used to induce inflammation (edema) in the paws of mice. Antiinflammatory drugs (e.g., BW755C and indomethacin) as well as cyproheptadine (mediator antagonist), theophylline (phosphodiesterase inhibitor) and guanabenz (α adrenoceptor agonist) showed the greatest efficacy in the carrageenan and zymosan models. Nonsteroidal antiinflammatory (NSAIDs) agents showed greater activity in the arachidonic acid (AA) paw edema model than the dual 5-lipoxygenase (LO)/cyclooxygenase (CO) inhibitors. The PAF model was insensitive to NSAIDs but showed some activity with drugs possessing inhibitory 5-LO activity (e.g., phenidone, BW755C) and the mediator antagonist, cyproheptadine. Suramin, a complement inhibitor, as expected, was active only against zymosan-induced edema. In conclusion, the inhibitory activities of dual 5-LO/CO inhibitors and NSAIDs were not different in the zymosan, carrageenan and AA edema models in the mouse; however, some selectivity for 5-LO inhibitors was observed in the PAF model.


Arachidonic Acid Indomethacin Theophylline Phosphodiesterase Platelet Activate Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    A. W. Ford-Hutchinson, J. R. Walker, N. S. Connor and M. J. H. Smith,Prostaglandins and leukocyte migration in inflammatory reactions. Agents and Actions7, 469–472 (1977).PubMedGoogle Scholar
  2. [2]
    C. A. Winter, E. A. Risley and G. W. Nuss,Carrageenan-induced edema in the hindpaw of the rat as an assay for anti-inflammatory drugs. Proc. Soc. Exp. Biol. Med.111, 544–547 (1962).Google Scholar
  3. [3]
    C. G. Van Arman, A. J. Begany, L. M. Miller and H. H. Pless,Some details of the inflammations caused by yeast and carrageenan. J. Pharmacol. Exp. Ther.150, 328–334 (1965).Google Scholar
  4. [4]
    R. Vinegar, W. Schreiber and R. Hugo,Biphasic development of carrageenan edema in rats. J. Pharmacol. Exp. Ther.166, 96–103 (1969).PubMedGoogle Scholar
  5. [5]
    J. Cottney, A. J. Lewis and D. J. Nelson,Arachidonic acid-induced paw edema in the rat. Br. J. Pharmacol.58, 311P (1976).Google Scholar
  6. [6]
    M. M. Goldenberg and R. D. Meurer,A pharmacologic analysis of the action of platelet-activating factor in the induction of hindpaw edema in the rat. Prostaglandins28, 271–278 (1984).CrossRefPubMedGoogle Scholar
  7. [7]
    K. F. Swingle and M. J. Reiter,Inhibition of PAF-acether-induced edema of the rat's paw. Agents Actions18, 359–365 (1986).PubMedGoogle Scholar
  8. [8]
    J. Damus and G. Remacle-Volon,Mast cell amines and the oedema induced by zymosan and carrageenans in rats. Eur. J. Pharmacol.121, 367–376 (1986).CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1987

Authors and Affiliations

  • W. Calhoun
    • 1
  • J. Chang
    • 1
  • R. P. Carlson
    • 1
  1. 1.Immunopharmacology Subdivision, Division of Experimental TherapeuticsWyeth Laboratories, Inc.PhiladelphiaUSA

Personalised recommendations